Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 6/20 | 0.34 |
| ▸ | DHFR | P00374 | 5/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776124 | 0.92 | GRM5 (0.36) | DCPSDHFRGRM5KDM4EL3MBTL1 | |
| SCHEMBL1775324 | 0.84 | GRM5 (0.36) | GRM5KDM4EL3MBTL1 | |
| SCHEMBL2513546 | 0.81 | LMNA (0.33) | DCPSDHFRGRM5KDM4ETLR7 | |
| SCHEMBL4792173 | 0.80 | TP53 (0.34) | DCPSDHFRGRM5KDM4ETLR7 | |
| SCHEMBL1775006 | 0.80 | MAPT (0.36) | DHFRGRM5KDM4ETLR7 | |
| SCHEMBL4707903 | 0.79 | TLR7 (0.37) | DHFRKDM4ETLR7 | |
| SCHEMBL4794357 | 0.78 | PIK3CB (0.33) | DCPSDHFRGRM5TLR7 | |
| SCHEMBL4792910 | 0.78 | TLR8 (0.37) | DCPSDHFRGRM5TLR7 | |
| SCHEMBL4705375 | 0.78 | GRM5 (0.33) | GRM5KDM4EL3MBTL1 | |
| SCHEMBL4791809 | 0.77 | POLB (0.39) | DCPSGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207725-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2011-08-25 | — | — | US | claimed |
| EP-1831226-A4 | CHIRAL FUSED 1,2 IMIDAZO 4,5-c RING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1831226-A2 | CHIRAL FUSED 1,2 IMIDAZO 4,5-c RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006074003-A2 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207725-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | IFNAR1, IFNG, IL4 | DCPS 3088/4885DHFR 160/4885GRM5 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.